eliglustat + CD30-targeted immunotherapy

This combination therapy regimen involves the administration of eliglustat, a small molecule glucosylceramide synthase inhibitor, in conjunction with CD30-targeted immunotherapies, specifically brentuximab vedotin (an antibody-drug conjugate) or CD30-directed CAR-T cell therapy. Developed by the Chinese PLA General Hospital, this approach is being investigated for the treatment of CD30-positive lymphomas. The therapeutic rationale is based on research suggesting that N-glycan modifications on the extracellular domain of target proteins can obstruct the formation of immune synapses between tumor cells and therapeutic agents like CAR-T cells. By inhibiting glycosphingolipid (GSL) synthesis, eliglustat is intended to reduce these glycan-mediated disruptions, thereby potentially enhancing the anti-tumor efficacy and binding of CD30-targeted agents.

Other names

Eliglustat Combined With CD30 Target ImmunotherapyEliglustat + Brentuximab VedotinEliglustat + CD30-targeting CAR-T Cell Therapy